Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
临床2期引进/卖出
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
ROSCREA, Ireland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that the United States Patent Office (“USPTO”) has issued a new composition of matter patent (Patent no. 11,643,409) and a method of use patent (Patent no. 11,827,631), both covering a novel crystal isoform of naronapride.
The composition of matter patent is the third new patent issued by the USPTO covering naronapride, a potential best-in-class oral, locally acting pan-GI prokinetic, which works by modulating two validated targets, 5-HT4 receptor agonism and D2 receptor antagonism, with a well-differentiated pharmaceutical, pharmacokinetics, safety and efficacy profile from other 5-HT4 agonists5-HT4 agonists. Naronapride is Renexxion’s lead drug candidate in mid-stage clinical development for gastroparesis and proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (“PPI-nrsGERD”), two high unmet need indications with limited or no currently available treatments. The new patents are currently being prosecuted worldwide including EP, Japan, and Greater China.
“The issuance of these new patents is an important milestone for the naronapride program and demonstrates our commitment to advancing this compound and making it widely accessible as a treatment for chronic GI diseases in large patient populations,” said Peter Milner M.D., FACC, Chairman and CEO of Renexxion. “We are pleased with naronapride’s development to date and continue to be excited about its potential to address unmet need for patients living with GI disorders requiring a prokinetic for use in upper or lower GI conditions.”
The current naronapride patent estate includes composition of matter, method of use and formulation patents. Renexxion is currently prosecuting these patents in EP, Japan, and greater China.
About Naronapride:
Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for unmet GI indications in the upper and lower GI tract. In scientific studies naronapride has been demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride was designed to be minimally absorbable and locally active in the gut lumen to potentially enhance efficacy and safety. Four positive Phase-II studies have been completed and naronapride is Phase-III ready in chronic idiopathic constipation (“CIC”), currently in Phase II-b study in gastroparesis, and Phase II-b ready in PPI-nrsGERD.
About Renexxion Ireland:
Renexxion Ireland Limited, a wholly owned Irish subsidiary of California-based Renexxion, LLC, is a privately held biopharmaceutical company committed to delivering new drugs to patients with GI disorders. Renexxion Ireland is currently collaborating with a leading European GI Licensing partner to advance naronapride through the later stages of development and commercialization in Greater Europe and certain other Australasian countries. Renexxion Ireland is currently advancing an additional research program in inflammatory bowel disease (“IBD”).
For information: http://www.rnexltd.ie.
Investor Relations Contact:
Irina Koffler, LifeSci Advisors, at ikoffler@lifesciadvisors.com, or on 1-917-734-7387
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。